Herein we report that RSV is potently oncolytic against androgen-sensitive LNCaP human prostate cancer cells in vitro and in vivo, and aberrant IFN-regulated signaling accounts for LNCaP cell susceptibility to RSV. The gene discussed is IFNA1; the disease is prostate cancer.